Cargando…

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola

Little information exists regarding Ebola vaccine rVSVΔG-ZEBOV-GP and pregnancy. The Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) randomized participants without blinding to immediate or deferred (18–24 weeks postenrollment) vaccination. Pregnancy was an exclusion criterion, but...

Descripción completa

Detalles Bibliográficos
Autores principales:	Legardy-Williams, Jennifer K., Carter, Rosalind J., Goldstein, Susan T., Jarrett, Olamide D., Szefer, Elena, Fombah, Augustin E., Tinker, Sarah C., Samai, Mohamed, Mahon, Barbara E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045819/ https://www.ncbi.nlm.nih.gov/pubmed/32017677 http://dx.doi.org/10.3201/eid2603.191018

Ejemplares similares

From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine
por: Herder, Matthew, et al.
Publicado: (2020)

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo
por: Hoff, Nicole A., et al.
Publicado: (2022)

Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine
por: Farooq, Fouzia, et al.
Publicado: (2016)

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
por: Tell, Joan G., et al.
Publicado: (2020)

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV
por: Azizi, Hiva, et al.
Publicado: (2023)

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
por: Agnandji, Selidji T., et al.
Publicado: (2017)

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
por: Rechtien, Anne, et al.
Publicado: (2017)

Recombinant Sudan virus and evaluation of humoral cross-reactivity between Ebola and Sudan virus glycoproteins after infection or rVSV-ΔG-ZEBOV-GP vaccination
por: Kainulainen, Markus H., et al.
Publicado: (2023)

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report
por: Gsell, Pierre-Stéphane, et al.
Publicado: (2017)

Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
por: Vianello, Eleonora, et al.
Publicado: (2022)

Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013–2016 West Africa Ebola outbreak in Guinea
por: Boum, Yap, et al.
Publicado: (2020)

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
por: Cross, Robert W., et al.
Publicado: (2020)

28. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO™) in Participants by Age, Sex, and Baseline GP-ELISA Titer: A Post Hoc Analysis of Three Phase 2/3 Trials
por: Simon, Jakub, et al.
Publicado: (2020)

Being Pregnant during the Kivu Ebola Virus Outbreak in DR Congo: The rVSV-ZEBOV Vaccine and Its Accessibility by Mothers and Infants during Humanitarian Crises and in Conflict Areas
por: Schwartz, David A.
Publicado: (2020)

Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report
por: Davis, Chris, et al.
Publicado: (2019)

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization()
por: Dahlke, Christine, et al.
Publicado: (2017)

Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines
por: Coller, Beth-Ann G., et al.
Publicado: (2022)

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
por: Monath, Thomas P., et al.
Publicado: (2019)

Ebola and Indirect Effects on Health Service Function in Sierra Leone
por: Bolkan, Håkon Angell, et al.
Publicado: (2014)

Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
por: Pejoski, David, et al.
Publicado: (2020)

Post-Ebola Syndrome, Sierra Leone
por: Scott, Janet T., et al.
Publicado: (2016)

Ebola wreaks havoc in Sierra Leone
por: Koroma, Mohamed, et al.
Publicado: (2015)

Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults
por: Halperin, Scott A, et al.
Publicado: (2019)

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
por: Henao-Restrepo, Ana Maria, et al.
Publicado: (2017)

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
por: Afolabi, Muhammed O, et al.
Publicado: (2022)

Titration methods for rVSV-based vaccine manufacturing
por: Gélinas, Jean-François, et al.
Publicado: (2020)

Post-Ebola sequelae among Ebola child survivors in Sierra Leone
por: Amuzu, Claudette, et al.
Publicado: (2021)

Author Correction: Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
por: Pejoski, David, et al.
Publicado: (2020)

Ebola response in Sierra Leone: The impact on children
por: Fitzgerald, Felicity, et al.
Publicado: (2016)

Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine
por: Santoro, Francesco, et al.
Publicado: (2021)

Quality of age data in the Sierra Leone Ebola database
por: Womack, Lindsay Shively, et al.
Publicado: (2020)

Frequency and spelling of names in the Sierra Leone Ebola Database
por: Alpren, Charles, et al.
Publicado: (2022)

Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model
por: Lee, Ha-Na, et al.
Publicado: (2021)

Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
por: de Wit, Emmie, et al.
Publicado: (2015)

Admissions and surgery as indicators of hospital functions in Sierra Leone during the west-African Ebola outbreak
por: Bolkan, Håkon A., et al.
Publicado: (2018)

The etiology of Ebola virus disease-like illnesses in Ebola virusnegative patients from Sierra Leone
por: Li, Wen-Gang, et al.
Publicado: (2016)

HIV prevalence in suspected Ebola cases during the 2014–2016 Ebola epidemic in Sierra Leone
por: Liu, William J., et al.
Publicado: (2019)

Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone
por: Manno, Daniela, et al.
Publicado: (2022)

Modeling the Impact of Interventions on an Epidemic of Ebola in Sierra Leone and Liberia
por: Rivers, Caitlin M., et al.
Publicado: (2014)

Phylodynamic Analysis of Ebola Virus in the 2014 Sierra Leone Epidemic
por: Volz, Erik, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_glot0jo6t7ipafn34kerpv1prc